A RANDOMIZED STUDY OF THE RELATIVE BIOAVAILABILITY, PHARMACODYNAMICS, AND SAFETY OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, AFTER SINGLE SUBCUTANEOUS ADMINISTRATION AT THREE DIFFERENT INJECTION SITES IN HEALTHY SUBJECTS

Authors
Category Primary study
JournalJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Year 2014
This article has no abstract
Epistemonikos ID: f4120c9b7adad9379d210d0c1a344be6f64ad115
First added on: Feb 05, 2025